Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

A Biotech Company Had $268 Million in Cash. After a Failed Drug Trial, It Announced a 46 Percent Workforce Cut

The biotech company is downsizing to fund another trial after a drug showed no meaningful benefit. The move comes just a year after its IPO.

A Biotech Company Had $268 Million in Cash. After a Failed Drug Trial, It Announced a 46 Percent Workforce Cut

We haven't written up this one. Inc. has the full story — the link below goes straight to it.

Read the original at inc.com →

More in Health & Medicine

More from Thursday 17 September →